On June 22, 2020, The Times UK published an Op Ed co-authored by AFAR experts Nir Barzilai, MD, Jim Mellon, and Sergey Young on the need to test generic drugs with the potential to reduce the impact of COVID-19, specifically the drug Metformin, which will be tested in the upcoming AFAR-funded Targeting Aging with Metformin (TAME) Trial.
Dr. Barzilai is AFAR’s Scientific Director, a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award winner, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Mr. Mellon is an AFAR Board member and recipient of our 2018 George E. and Mary J. Doty Award recipient.
Mr. Young is also an AFAR Board member, author, and Founder of the Longevity Vision Fund.
The published Op Ed is available by subscription only here. AFAR is pleased to share a transcript courtesy of Dr. Barzilai here.
Find more articles and resources on COVID-19 penned by AFAR experts here.
